Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Income from Continuing Operations of 45514000.0 in Q1 2026, down 17.58% quarter-over-quarter from 38708000.0 in Q4 2025, and down 14.14% on a YoY basis from 53008828.32 in Q1 2025.
Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tango Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45514000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 14.14% year-over-year to 45514000.0; the TTM figure through Mar 2026 stood at 107191000.0 (up 18.93% YoY), while the FY2025 annual figure was 101594000.0, up 22.03% from the prior year.
- Income from Continuing Operations was 45514000.0 for Q1 2026 at Tango Therapeutics, down from 38708000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 15884000.0 in Q3 2025 to a low of 45514000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 28661176.47 across 5 years, with a median of 29060000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 453.26% in 2022, then soared 154.46% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 29060000.0 in 2022, then fell by 5.86% to 30763000.0 in 2023, then fell by 22.29% to 37621000.0 in 2024, then dropped by 2.89% to 38708000.0 in 2025, then declined by 17.58% to 45514000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 45514000.0 (Q1 2026), 38708000.0 (Q4 2025), and 15884000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | -45.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.51 Mn |
| Dec 31, 2025 | -38.71 Mn |
| Sep 30, 2025 | 15.88 Mn |
| Jun 30, 2025 | -38.85 Mn |
| Mar 31, 2025 | -39.88 Mn |
| Dec 31, 2024 | -37.62 Mn |
| Sep 30, 2024 | -29.17 Mn |
| Jun 30, 2024 | -25.55 Mn |
| Mar 31, 2024 | -37.91 Mn |
| Dec 31, 2023 | -30.76 Mn |
| Sep 30, 2023 | -22.26 Mn |
| Jun 30, 2023 | -20.71 Mn |
| Mar 31, 2023 | -28.01 Mn |
| Dec 31, 2022 | -29.06 Mn |
| Sep 30, 2022 | -29.05 Mn |
| Jun 30, 2022 | -24.86 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -22.05 Mn |
| Sep 30, 2021 | -19.59 Mn |
| Jun 30, 2021 | -4.49 Mn |